Drug Type Recombinant polypeptide, Biosimilar |
Synonyms Semaglutide Biosimilar (Beijing Zhitai Biomedical Technology Co., Ltd.), 司美格鲁肽 生物类似药(北京质肽生物医药科技有限公司), 司美格鲁肽生物类似药(通化东宝) + [4] |
Target |
Mechanism GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cardiovascular Diseases | Phase 3 | CN | 18 Jul 2024 | |
Diabetes Mellitus, Type 2 | Phase 3 | CN | 18 Jul 2024 | |
Obesity | Phase 2 | - | - |